# Pricing of Compounded vs Branded Tirzepatide in 2026

Canonical source: https://retacompare.com/research/pricing-compounded-vs-branded-2026-17

Compounded Peptides · 2026-02-12


    As of early 2026, compounded tirzepatide pricing has compressed significantly compared to the 2023–2024 peak. Branded Zepbound now costs approximately $500–$650 per month through Eli Lilly's direct-to-patient LillyDirect program, narrowing the gap with compounded alternatives that typically range from $249–$399 per month. The pricing convergence reflects both Eli Lilly's direct-to-consumer strategy and the increased regulatory and legal risk premium on compounded preparations. Telehealth platforms offering compounded tirzepatide have also restructured into broader 'personalized' formulations in an attempt to demonstrate clinical differentiation under 503A.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources